Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02452801 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetics and Safety of ALKS 5461 in Healthy Subjects and Subjects With Hepatic Impairment and Normal Hepatic Function
A Phase 1 study, sponsored by Alkermes.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT02452801 is a Phase 1 study that has completed, run by Alkermes. The registered enrollment target is 40 participants.
The verdict
NCT02452801, a Phase 1 study, has completed, sponsored by Alkermes.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
This study will evaluate the effect of various degrees of hepatic function on the pharmacokinetics and safety of ALKS 5461.
Interventions
- DRUG ALKS 5461
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2015-05 |
| Est. Completion | 2015-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02452801
The ClinicalTrials.gov registry entry for NCT02452801 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alkermes, which has 66 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ALKS 5461 is the first listed.
NCT02452801 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02452801 about?
NCT02452801 is a clinical study titled "Pharmacokinetics and Safety of ALKS 5461 in Healthy Subjects and Subjects With Hepatic Impairment and Normal Hepatic Function". This study will evaluate the effect of various degrees of hepatic function on the pharmacokinetics and safety of ALKS 5461.
What is the current status of trial NCT02452801?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2015-05. Estimated completion is 2015-12.
What interventions are being tested in trial NCT02452801?
The interventions under investigation include: ALKS 5461 (DRUG).
Who is sponsoring clinical trial NCT02452801?
This trial is sponsored by Alkermes, which has 66 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.